| Literature DB >> 31217360 |
Masao Kakoki1, Edward M Bahnson1,2, John R Hagaman1, Robin M Siletzky2, Ruriko Grant1, Yukako Kayashima1, Feng Li1, Esther Y Lee1, Michelle T Sun1, Joan M Taylor1, Jessica C Rice3, Michael F Almeida3, Ben A Bahr3, J Charles Jennette1, Oliver Smithies1, Nobuyo Maeda-Smithies1.
Abstract
Engulfment and cell motility protein 1 (ELMO1) is part of a guanine nucleotide exchange factor for Ras-related C3 botulinum toxin substrate (Rac), and ELMO1 polymorphisms were identified to be associated with diabetic nephropathy in genome-wide association studies. We generated a set of Akita Ins2C96Y diabetic mice having 5 graded cardiac mRNA levels of ELMO1 from 30% to 200% of normal and found that severe dilated cardiomyopathy develops in ELMO1-hypermorphic mice independent of renal function at age 16 weeks, whereas ELMO1-hypomorphic mice were completely protected. As ELMO1 expression increased, reactive oxygen species indicators, dissociation of the intercalated disc, mitochondrial fragmentation/dysfunction, cleaved caspase-3 levels, and actin polymerization increased in hearts from Akita mice. Cardiomyocyte-specific overexpression in otherwise ELMO1-hypomorphic Akita mice was sufficient to promote cardiomyopathy. Cardiac Rac1 activity was positively correlated with the ELMO1 levels, and oral administration of a pan-Rac inhibitor, EHT1864, partially mitigated cardiomyopathy of the ELMO1 hypermorphs. Disrupting Nox4, a Rac-independent NADPH oxidase, also partially mitigated it. In contrast, a pan-NADPH oxidase inhibitor, VAS3947, markedly prevented cardiomyopathy. Our data demonstrate that in diabetes mellitus ELMO1 is the "rate-limiting" factor of reactive oxygen species production via both Rac-dependent and Rac-independent NADPH oxidases, which in turn trigger cellular signaling cascades toward cardiomyopathy.Entities:
Keywords: Cardiology; Cardiovascular disease
Year: 2019 PMID: 31217360 PMCID: PMC6629098 DOI: 10.1172/jci.insight.127660
Source DB: PubMed Journal: JCI Insight ISSN: 2379-3708